To further corroborate the role of cyclin E in resistance to fulvestrant, we analyzed the expression of cyclin E2 by IHC in metastatic tumor samples from a cohort of 83 ER+ breast cancer patients treated with fulvestrant [21]. Here, CCNE2 is linked to breast carcinoma.